Etoxib

Etoricoxib

Symptomatic treatment of pain & inflammation in OA & RA; ankylosing spondylitis; acute gout.

Pain & inflammation in OA Adult, childn 16-17 yr 30 mg once daily, may be increased to 60 mg once daily if necessary. Pain & inflammation in RA, ankylosing spondylitis Adult, childn 16-17 yr 60 mg once daily, may increase to 90 mg once daily if necessary. Acute gout Adult, childn 16-17 yr 120 mg once daily for max of 8 days. Moderate hepatic impairment (Child-Pugh score 7-9) Max: 60 mg every other day or 30 mg once daily, mild hepatic impairment (Child-Pugh score 5-6) 60 mg once daily.

Should be taken with food.

Active GI bleeding & ulceration; cerebrovascular disease; inflammatory bowel disease; ischaemic heart disease, mild to severe heart failure, peripheral arterial disease, uncontrolled HTN (persistently >140/90 mmHg).

Allergic disorders. Cardiac impairment; coagulation defects; connective tissue disorders; dehydration; HTN; left ventricular dysfunction; oedema. May exacerbate Crohn's disease & ulcerative colitis. History of cardiac failure. Risk factors for CV events. Increased risk of GI bleeding & fluid retention. Use lowest effective dose for shortest possible duration. Monitor renal function. Severe hepatic impairment (Child-Pugh ≥10). Renal impairment (estimated GFR <30 mL/min/1.73 m² in adult & childn). Avoid during 3rd trimester of pregnancy. Lactation. Elderly.

Ecchymosis; fatigue; flu-like symptoms; palpitation.

Increased plasma conc of ethinylestradiol, cardiac glycosides. Reduced plasma conc by rifampicin. Increased risk of renal impairment & antagonized hypotensive effect w/ ACE inhibitors, angiotensin II receptor antagonists. Antagonized hypotensive effect of adrenergic neurone blockers, aliskiren, α- & β-blockers, Ca-channel blockers, clonidine, diazoxide, hydralazine, methyldopa, minoxidil, moxonidine, nitrates, Na nitroprusside. Increased risk of hyperkalemia w/ aldosterone antagonists, K-sparing diuretics. Increased risk of bleeding w/ SSRIs, clopidogrel, dabigatran, edoxaban, erlotinib, heparins, iloprost, pentoxifylline, prasugrel, venlafaxine. Increased side effects w/ aspirin, other NSAIDs. Increased risk of toxicity of baclofen, lithium, MTX. Increased risk of nephrotoxicity w/ ciclosporin, penicillamine, tacrolimus. Increased risk of GI bleeding & ulceration w/ corticosteroids, nicorandil. Enhanced anticoagulant effect of coumarins, phenindion. Increased risk of nephrotoxicity & antagonized diuretic effect w/ diuretics. Increased side effects & haemorrhage w/ ketorolac. Reduced renal excretion of pemetrexed. Antagonized diuretic effect of K canrenoate. Increased risk of convulsions w/ quinolones. Increased plasma conc by ritonavir. Enhanced effects of sulfonylureas. Increased haematological toxicity w/ zidovudine. Avoid high doses w/ mifamurtide.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

D